Drug profile · INN
risdiplam
EVRYSDI
risdiplam (EVRYSDI) is a smn2 pre-mrna positive modulator. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Drug details — risdiplam
- US status
- approved
- Class
- Musculo-skeletal system (M09)
- Route
- ORAL
- Patents
- 2
- Programs
- 4
- Data quality
- 0.84
Quick answer
risdiplam (EVRYSDI) is a smn2 pre-mrna positive modulator. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
SMN2 pre-mRNA positive modulator
Primary target: SMN2 pre-mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is risdiplam?
risdiplam (EVRYSDI) is a smn2 pre-mrna positive modulator. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for risdiplam?
EVRYSDI is a marketed brand name for risdiplam. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of risdiplam?
risdiplam has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.